2seventy bio Inc (NASDAQ: TSVT): How It Has Performed & Trended

In the last trading session, 1.08 million shares of the 2seventy bio Inc (NASDAQ:TSVT) were traded, and its beta was 1.84. Most recently the company’s share price was $4.94, and it changed around -$0.85 or -14.68% from the last close, which brings the market valuation of the company to $253.47M. TSVT currently trades at a discount to its 52-week high of $12.69, offering almost -156.88% off that amount. The share price’s 52-week low was $1.53, which indicates that the current value has risen by an impressive 69.03% since then. We note from 2seventy bio Inc’s average daily trading volume that its 10-day average is 1.42 million shares, with the 3-month average coming to 1.47 million.

2seventy bio Inc (NASDAQ:TSVT) trade information

Instantly TSVT has showed a red trend with a performance of -14.68% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 15.69% year-to-date, but still up 0.82% over the last five days. On the other hand, 2seventy bio Inc (NASDAQ:TSVT) is -12.41% down in the 30-day period. We can see from the shorts that 5.25 million shares have been sold at a short interest cover period of 5.49 day(s).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The consensus price target as assigned by Wall Street analysts is $26, which translates to bulls needing to increase their stock price by 81.0% from its current value. Analyst projections state that TSVT is forecast to be at a low of $26 and a high of $26.

2seventy bio Inc (TSVT) estimates and forecasts

2seventy bio Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 26.02 percent over the past six months and at a 69.23% annual growth rate that is well above the industry average of 13.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 30.60% in revenue this quarter, and will report an increase of 28.90% in the next quarter. The year-over-year growth rate is expected to be -17.50%, down from the previous year.

Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $15.28 million in revenue for the current quarter. 6 analysts expect 2seventy bio Inc to make $19.09 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $22.3 million and $36.05 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -31.50%. Forecasts for the next quarter put sales growth at -47.00%.

TSVT Dividends

2seventy bio Inc’s next quarterly earnings report is expected to be released around May 01 and May 06.

2seventy bio Inc (NASDAQ:TSVT)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 2.06% of 2seventy bio Inc shares, and 98.25% of them are in the hands of institutional investors. The stock currently has a share float of 100.32%. 2seventy bio Inc stock is held by 171 institutions, with Kynam Capital Management, LP being the largest institutional investor. By Jun 29, 2023, it held 9.69% of the shares, which is about 4.89 million shares worth $49.49 million.

Blackrock Inc., with 8.19% or 4.14 million shares worth $41.85 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

Vanguard Specialized-Health Care Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Jul 30, 2023. The former held 2.05 million shares worth $15.53 million, making up 4.06% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 1.95 million shares worth around $10.1 million, which represents about 3.86% of the total shares outstanding.